NASDAQ:HEPA

Hepion Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy HEPA

*Your capital is at risk

$0.0600

-0.0030 (-4.76%)

At Close: Jun 03, 2026

Hepion Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 21.86M and sold 0 HEPA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	21.86M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 21, 2026 Buy	Common Stock, par value $0.0001 per share P-Purchase	Stetz Gary S. Interim CEO	CEO / President	1 250 000 Value: $50.0K
Apr 21, 2026 Buy	Common Stock, par value $0.0001 per share P-Purchase	Appajosyula Sireesh Director	Director	1 250 000 Value: $50.0K
Apr 21, 2026 Buy	Common Stock, par value $0.0001 per share P-Purchase	Lopriore Vincent S Executive Chairman	CEO / President	5 000 000 Value: $200.0K
Apr 21, 2026 Buy	Common Stock, par value $0.0001 per share P-Purchase	Lopriore Vincent S Executive Chairman	CEO / President	1 250 000 Value: $50.0K
Apr 21, 2026 Buy	Common Stock, par value $0.0001 per share P-Purchase	Purcell Michael J. Director	Director	1 250 000 Value: $50.0K
Mar 16, 2026 Buy	Common Stock, par value $0.0001 per share	Lopriore Chase Director	Director	0 Value: $0
Mar 16, 2026 Buy	Common Stock J-Other	Appajosyula Sireesh	Director	0 Value: $0
Mar 16, 2026 Buy	Common Stock J-Other	Lopriore Vincent S Executive Chairman	CEO / President	0 Value: $0
Mar 16, 2026 Buy	Common Stock J-Other	Stetz Gary S. Chief Executive Officer	CEO / President	0 Value: $0
Mar 06, 2024 Buy	Restricted Stock Units A-Award	Purcell Michael J. Director	Director	50 000 Value: $0
Mar 06, 2024 Buy	Restricted Stock Units A-Award	Purcell Michael J. Director	Director	50 000 Value: $0
Mar 05, 2024 Buy	Common Stock J-Other	Purcell Michael J.	Director	0 Value: $0
Mar 05, 2024 Buy	Common Stock J-Other	Purcell Michael J.	Director	0 Value: $0
Feb 19, 2024 Buy	Stock Options A-Award	Block Timothy M. Director	Director	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Jacob Gary S Director	Director	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Lbiati Kaouthar Director	Director	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Brancaccio John P Chairman	CEO / President	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Brancaccio John P Chairman	CEO / President	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Lbiati Kaouthar Director	Director	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Jacob Gary S Director	Director	85 000 Value: $217.6K
Feb 19, 2024 Buy	Stock Options A-Award	Block Timothy M. Director	Director	85 000 Value: $217.6K
Nov 27, 2023 Buy	Common Stock P-Purchase	Wijngaard Peter Director	Director	2 500 Value: $8K
Nov 27, 2023 Buy	Common Stock P-Purchase	Wijngaard Peter Director	Director	2 500 Value: $8K
Nov 24, 2023 Buy	Common Stock P-Purchase	Wijngaard Peter Director	Director	2 500 Value: $8K
Nov 24, 2023 Buy	Common Stock P-Purchase	Wijngaard Peter Director	Director	2 500 Value: $8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HEPION PHARMACEUTICALS, INC.

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH...

Read Full Profile Here